Motley Fool Asset Management LLC Buys 5,913 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Motley Fool Asset Management LLC raised its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 10.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,872 shares of the company’s stock after purchasing an additional 5,913 shares during the quarter. Motley Fool Asset Management LLC owned 0.11% of Inari Medical worth $3,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of Inari Medical by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock worth $287,354,000 after acquiring an additional 30,702 shares during the last quarter. Jennison Associates LLC lifted its stake in Inari Medical by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after purchasing an additional 186,617 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Inari Medical by 9.1% in the 4th quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock worth $54,546,000 after purchasing an additional 89,108 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Inari Medical by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 465,962 shares of the company’s stock valued at $23,787,000 after purchasing an additional 11,990 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Inari Medical by 5.2% during the 4th quarter. Principal Financial Group Inc. now owns 308,903 shares of the company’s stock valued at $15,769,000 after buying an additional 15,368 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price target (down from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Piper Sandler increased their target price on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a report on Tuesday, January 7th. Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Oppenheimer initiated coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price for the company. Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $68.00.

Inari Medical Stock Performance

NASDAQ NARI opened at $79.97 on Thursday. The stock has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a fifty-two week low of $36.73 and a fifty-two week high of $79.99. The stock has a 50 day simple moving average of $79.90 and a two-hundred day simple moving average of $62.16.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.60% of the stock is owned by corporate insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.